Defining pseudoprogression in glioblastoma multiforme

Elke Van Mieghem(VIB-KU Leuven Center for Cancer Biology), Paul M. Clément(Universitair Ziekenhuis Leuven), Oliver Bechter(Universitair Ziekenhuis Leuven), Frank Van Calenbergh(Universitair Ziekenhuis Leuven), Guy Wilms(KU Leuven), Johan Menten(Catholic University of America), Stefaan Van Gool(Centrum für Integrierte Onkologie), Steven De Vleeschouwer(KU Leuven), Philippe Demaerel(KU Leuven), Agnieszka Woźniak(VIB-KU Leuven Center for Cancer Biology), Raf Sciot(KU Leuven), Yasmyne Geussens(KU Leuven)
European Journal of Neurology
May 17, 2013
10.1111/ene.12192
Cited by 55

Related Papers

Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
|The Lancet Oncology|2016|504
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
|Journal of Clinical Oncology|2010|445